^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    TP53 mutation + ALK positive

    i
    Other names: NBLST3, CD246, Anaplastic Lymphoma Kinase, Anaplastic Lymphoma Kinase (Ki-1), CD246 Antigen, Mutant Anaplastic Lymphoma Kinase, ALK, ALK Receptor Tyrosine Kinase, Anaplastic Lymphoma Receptor Tyrosine Kinase, ALK Tyrosine Kinase Receptor, TP53, Tumor Protein P53, Cellular Tumor Antigen P53, Phosphoprotein P53, Tumor Protein P53, Antigen NY-CO-13, Transformation-Related Protein 53, Mutant Tumor Protein 53, P53 Tumor Suppressor, Tumor Suppressor P53, Tumor Protein 53, BMFS5, TRP53, BCC7, LFS1
    Entrez ID:
    238; 7157
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    4years
    Colorectal Adenocarcinomas Harboring ALK Fusion Genes: A Clinicopathologic and Molecular Genetic Study of 12 Cases and Review of the Literature. (PubMed, Am J Surg Pathol)
    Aberration of p53 signaling, TP53 mutations, and/or nuclear accumulation of p53 protein was seen in 9 cases. ALK fusion colorectal carcinomas are a distinct and rare subtype of colorectal cancers displaying some features of mismatch repair-deficient tumors.
    Clinical • Review • Journal • PD(L)-1 Biomarker
    |
    PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • TP53 (Tumor protein P53) • PTEN (Phosphatase and tensin homolog) • EML4 (EMAP Like 4) • STRN (Striatin) • CDX2 (Caudal Type Homeobox 2) • MUC2 (Mucin 2)
    |
    TP53 mutation • MSI-H/dMMR • BRAF mutation • ALK positive • PTEN mutation • ALK fusion • STRN-ALK fusion • TP53 mutation + ALK positive • TILs
    4years
    EBP2, a novel NPM-ALK-interacting protein in the nucleolus, contributes to the proliferation of ALCL cells by regulating tumor suppressor p53. (PubMed, Mol Oncol)
    In Ba/F3 cells transformed by NPM-ALK and Ki-JK cells, p53 activation induced by knockdown of EBP2 was significantly inhibited by Akt inhibitor GDC-0068, mTORC1 inhibitor rapamycin, and knockdown of Raptor, an essential component of mTORC1. These results suggest that the knockdown of EBP2 triggered p53 activation through the Akt-mTORC1 pathway in NPM-ALK-positive cells. Collectively, the present results revealed the critical repressive mechanism of p53 activity by EBP2 and provide a novel therapeutic strategy for the treatment of ALCL.
    Journal
    |
    ALK (Anaplastic lymphoma kinase) • TP53 (Tumor protein P53) • NPM1 (Nucleophosmin 1)
    |
    TP53 mutation • ALK positive • TP53 mutation + ALK positive
    |
    ipatasertib (RG7440) • sirolimus
    4years
    Distribution of EML4-ALK fusion variants and clinical outcomes in patients with resected non-small cell lung cancer. (PubMed, Lung Cancer)
    This study illustrated the patterns of EML4-ALK fusion variants and gene profiles in patients with resected NSCLC. Advanced T stage and EML4-ALK variant 3 were associated with worse prognosis. The role of TP53 mutations in prognosis is worthy of further study.
    Clinical • Clinical data • Journal
    |
    ALK (Anaplastic lymphoma kinase) • TP53 (Tumor protein P53) • EML4 (EMAP Like 4)
    |
    TP53 mutation • ALK positive • ALK rearrangement • EML4-ALK fusion • ALK fusion • TP53 mutation + ALK positive • EML4-ALK variant 1
    over4years
    [VIRTUAL] Pathology and Pathogenesis of T-Cell Lymphoma (SOHO 2020)
    Recognizing this unique process is important as mimics NK/T cell lymphoma and can result in erroneous diagnosis, leading to aggressive chemotherapy. The etiology of this process is unknown.
    PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • TP53 (Tumor protein P53) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • NPM1 (Nucleophosmin 1) • CD20 (Membrane Spanning 4-Domains A1) • DNMT3A (DNA methyltransferase 1) • CD8 (cluster of differentiation 8) • TNFRSF8 (TNF Receptor Superfamily Member 8) • TET2 (Tet Methylcytosine Dioxygenase 2) • JAK3 (Janus Kinase 3) • NCAM1 (Neural cell adhesion molecule 1) • ALK1 (Activin A Receptor Like Type 1) • STAT5B (Signal Transducer And Activator Of Transcription 5B) • SYK (Spleen tyrosine kinase) • IRF4 (Interferon regulatory factor 4) • TBX21 (T-Box Transcription Factor 21) • TYK2 (Tyrosine Kinase 2) • SH2B3 (SH2B Adaptor Protein 3) • TP63 (Tumor protein 63) • GATA3 (GATA binding protein 3) • TCL1A (TCL1 Family AKT Coactivator A)
    |
    PD-L1 expression • TP53 mutation • ALK positive • IDH2 mutation • DNMT3A mutation • ALK fusion • TET2 mutation • TNFRSF8 positive • TNFRSF8 expression • ALK translocation • ALK negative • NPM1-ALK fusion • STAT3 mutation • TP53 mutation + ALK positive • JAK3 mutation • IDH2 R172